CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has received certificates of registration for the trademark CANNASEN^® in Australia. This marks a step for securing the brand in the Company’s expansion on the global market.

CS MEDICA announces today that the trademark offices in Australia have approved CS MEDICA’s trademark CANNASEN^®.

“One of the things to secure when building a global business is trademarks. CS MEDICA has always been active in filing patents to secure the future of our products, but we also see the value of securing our brands with trademark registration. This is an additional important step we are taking in our global sales strategy.” says CEO Lone Henriksen.

The trademark approval of CANNASEN^® is an important step in CS MEDICA’s market strategy to expand sales of its product line CANNASEN^® in the global market. The trademark registration no. for CANNASEN^® in Australia is 2233150 and is valid until November 19, 2028.

Trademarks as of October 2023;

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating globally within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments with CBD for autoimmune and stress-related disorders under the trademark CANNASEN® or own-label options.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com, and LinkedIn.